The answer is C: High altitude pulmonary edema (HAPE) is the leading cause of altitude-related death (
1). It is characterized by non-cardiogenic pulmonary edema occurring with rapid ascent to altitudes above 2,500 m (
1-
3). This patient travelled from San Antonio, TX with altitude of 235 m to Winter Park, CO with altitude of 2,800 m. Risk factors for development of HAPE include prior history of altitude illness, higher altitude, rapid ascent, male sex, cold ambient temperatures, pre-existing respiratory infections, and intense exercise (
1-
3). Estimates of HAPE incidence vary, but have been reported as high as 4% in un-acclimatized mountaineers above 4,600 m (
2). Onset of HAPE typically occurs within 1-4 days of ascent to altitude (
3). Symptoms include fatigue, dyspnea on exertion, decreased exercise tolerance, low-grade fever, and dry cough which sometimes progresses to become productive of pink, frothy, sputum (
2,
3). On physical examination, patients with HAPE are tachycardic, tachypneic, and hypoxic, frequently with low-grade fevers (
1-
3). Pulmonary examination reveals inspiratory crackles, initially in the right middle lobe, and becoming more diffuse and bilateral later in the illness (
1-
3). Chest x-ray (CXR) classically shows patchy perihilar opacities, sometimes with interstitial edema and pleural effusions. Heart size is normal, which is consistent with no cardiogenic pulmonary edema (
3). The cornerstones of HAPE treatment are immediate descent to lower altitude and supplemental oxygen (
1-
3). If descent is not possible or supplemental oxygen not available, pharmacotherapy with nifedipine may be considered as the next line of treatment, with the goal being to decrease pulmonary artery pressure (
1,
3) Several studies have suggested benefit with long acting beta agonists (e.g. salmeterol) and with phosphodiesterase-5 inhibitors, but no strong evidence for either exists (
1,
3). Similarly, HAPE is best prevented by gradual ascent to altitude (
1-
3). Pharmacologic prophylaxis can be considered, particularly in those with a history of HAPE, with nifedipine as the first-line agent and other potential options including phosphodiesterase-5 inhibitors, long acting beta agonists, and dexamethasone (
1-
3).
Atypical organisms account for up to 40% of community-acquired pneumonia (
4). Patients usually present with fevers and productive cough (
4). Lung examination may reveal rales and wheezing (
4). Hypoxia is rare (
4). CXR may reveal patchy or circumscribed opacities (
4). Pulmonary embolism (PE) may present with a sudden episode of SOB at rest (
5). CXR is non-diagnostic in patients with PE and most commonly shows atelectasis, non-specific parenchymal abnormalities, or pleural effusions (
5). Less commonly, the classic signs of a peripheral wedge-shaped opacity may be seen (
5). Exercise-induced bronchospasm causes dyspnea and chest tightness during or after exercise (
6). Physical examination is usually unremarkable with occasional wheezing (
6). CXR is usually normal or may show increased bronchial wall thickening or flattening of the diaphragm (
6). Pneumothorax is a relatively common condition among adults and can present with dyspnea and pleuritic chest pain (
5). Physical examination typically reveals decreased chest excursion as well as decreased breath sounds on the affected side (
5). CXR usually demonstrates a visceral pleural line, beyond which no pulmonary markings are present and possible mediastinal shift (
5,
7).